- Phototherapeutic Keratectomy
- Amniotic Membrane Transplants
- Anterior Stromal Puncture
- Conjunctival Flaps
Corneal Endothelial Dystrophy Market was valued at USD 168 billion in 2022 and is poised to grow at a CAGR of 7.5% over 2023-2029. Corneal endothelial dystrophy is a group of rare hereditary disorders characterized by bilateral abnormal deposition of substances in the cornea. Based on the diagnosis type, the cornea examination and grading segment is anticipated to dominate the corneal endothelial dystrophy market share over the forecast period. According to the American Academy of Ophthalmology, congenital corneal opacities have a prevalence of 6:1,00,000 in newborns and 3:1,00,000 excluding congenital glaucoma patients. With an increasingly aging population, awareness of the disorder is also increasing, driving the corneal endothelial dystrophy market growth. However, the side effects associated with the treatment procedures might hinder the market growth. Initiatives by the government and increasing reimbursement policies are opportunities for the growth of the market.
Corneal Endothelial Dystrophy Market Key Developments:
- In May 2023, Trefoil Therapeutics released updated efficacy data from the phase-II STORM trial in Fuchs endothelial dystrophy for TTHX-1114.
Corneal Endothelial Dystrophy Market Summary
Study Period
2023-29
Base Year
2022
CAGR
7.5%
Largest Market
North America
Fastest Growing Market
North America
Corneal Endothelial Dystrophy Market Dynamics
There has been an increase in technologies involved in the diagnosis and treatment of the disease with an increased clinical trial in the eye disease segment owing to the growing healthcare expenditures. For Instance, Rhopressa (Netarsudil ophthalmic solution), developed by Aerie Pharmaceuticals is used in the treatment of Fuchs endothelial corneal dystrophy. Thus, the increased awareness, research, and development for rare disorders will lead to the growth of the market within the forecast period. Whereas the high cost of treatment could pose as a restraining factor for the market growth.
North-America Got Significant Share of
Corneal Endothelial Dystrophy Market Regional Analysis
The corneal endothelial dystrophy market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the World Health Organization, there will be 2 billion individuals at age 65 or over by 2050. Moreover, the total number of people with Fuchs endothelial corneal dystrophy worldwide will increase from 300 million in 2020 to 415 million in 2050. The North America Corneal Endothelial Dystrophy market is expected to dominate the market over the forecast period, majorly because of the highly developed healthcare systems in the United States and Canada, as well as the strong presence of major market players in the region. The Asia Pacific region is also expected to witness growth due to the rising awareness, and increased diagnostic rates. In the European countries, the increased research and development activities will drive the market growth.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The corneal endothelial dystrophy market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Corneal Endothelial Dystrophy Market Segmentation
By Treatment
By Disease Type
- Congenital Hereditary Endothelial Dystrophy 1
- Congenital Hereditary Endothelial Dystrophy 2
- Posterior Polymorphous Corneal Dystrophy
- Fuchs Endothelial Corneal Dystrophy
By Diagnosis
- Cornea Examination and Grading
- Corneal Tomography
- Corneal Pachymetry
- Corneal Cell Count
- Others
By End User
- Hospitals
- Clinics
- Others
Frequently Asked Questions
The corneal endothelial dystrophy market was valued at USD 168 billion in 2022 and is expected to grow at a 7.5% CAGR over the forecast period 2023 – 2029.
Initiatives by the government and increasing reimbursement policies are key opportunities for the corneal endothelial dystrophy market.
An increasing aging population and a rise in awareness of the disorder are the growth drivers in the corneal endothelial dystrophy market.
Kowa Company, Ltd., Trefoil Therapeutics, Alcon, Price Vision Group, ProQR Therapeutics, Emmecell, Pfizer Inc., GlaxoSmithKline plc., Bausch Health Companies Inc., Bayer AG, Allergan, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Novartis AG are a few companies operating in the Corneal Endothelial Dystrophy market.
- Kowa Company, Ltd.
- Trefoil Therapeutics
- Alcon
- Price Vision Group
- ProQR Therapeutics
- Emmecell
- Pfizer Inc.
- GlaxoSmithKline plc.
- Bausch Health Companies Inc.
- Bayer AG
- Allergan
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Novartis AG